Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY25 results · Jul–Sep 2024
Suven Life Sciences reported revenue from operations of ₹2.57 crore (down 15.9% from Q2 FY24) and net loss of ₹49.64 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.57 | 3.06 | −15.9% | 1.01 | +155.8% |
| Other income | 4.04 | 5.14 | −21.5% | 4.01 | +0.7% |
| Total income | 6.61 | 8.20 | −19.4% | 5.01 | +31.8% |
| Profit before tax | (49.64) | (12.68) | Loss widened | (28.04) | Loss widened |
| Net profit for the period | (49.64) | (12.68) | Loss widened | (28.04) | Loss widened |
| EPS, basic (₹) | (2.27) | (0.58) | Loss widened | (1.29) | Loss widened |
| Net margin (%) | -1929.5 | -414.4 | -2787.2 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.57 | 3.06 | −15.9% | 1.01 | +155.8% |
| Other income | 4.03 | 5.14 | −21.5% | 3.93 | +2.6% |
| Total income | 6.61 | 8.20 | −19.4% | 4.94 | +33.8% |
| Profit before tax | (11.07) | 2.75 | Turned loss | (7.67) | Loss widened |
| Net profit for the period | (11.07) | 2.75 | Turned loss | (7.67) | Loss widened |
| EPS, basic (₹) | (0.51) | 0.13 | Turned loss | (0.35) | Loss widened |
| Net margin (%) | -430.3 | 90.0 | -762.0 |
Consolidated
- Filed with BSE
- 29 Oct 2024, 18:12 IST
- Board meeting
- 29 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2024, 18:12 IST
- Board meeting
- 29 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE